000275766 001__ 275766
000275766 005__ 20240229154945.0
000275766 0247_ $$2doi$$a10.1016/j.cpet.2023.03.003
000275766 0247_ $$2pmid$$apmid:37117122
000275766 0247_ $$2ISSN$$a1556-8598
000275766 0247_ $$2ISSN$$a1879-9809
000275766 0247_ $$2altmetric$$aaltmetric:146865464
000275766 037__ $$aDKFZ-2023-00865
000275766 041__ $$aEnglish
000275766 082__ $$a610
000275766 1001_ $$0P:(DE-HGF)0$$aKoerber, Stefan A$$b0$$eLast author
000275766 245__ $$aRadiation Therapy Planning Using Fibroblast Activation Protein Inhibitor.
000275766 260__ $$aOrlando, Fla. [u.a.]$$bElsevier$$c2023
000275766 3367_ $$2DRIVER$$aarticle
000275766 3367_ $$2DataCite$$aOutput Types/Journal article
000275766 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1687859766_19595$$xReview Article
000275766 3367_ $$2BibTeX$$aARTICLE
000275766 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275766 3367_ $$00$$2EndNote$$aJournal Article
000275766 500__ $$a#LA:E050# / 2023 Jul;18(3):369-380
000275766 520__ $$aComputed tomography (CT), MR imaging, and PET with fluorodeoxyglucose F18/CT are commonly used for radiation therapy planning; however, issues including precise nodal staging on CT or false positive results on PET/CT limit their usability. Clinical trials using fibroblast activation protein ligands for additional imaging have provided promising results regarding staging and target volume delineation-particularly suitable for sarcoma, some gastrointestinal tumors, head and neck tumors, and lung and pancreatic cancer. Although further prospective trials are necessary to identify clinical settings for its application in radiation oncology, fibroblast activation protein inhibitor PET/CT indisputably represents an excellent opportunity for assisting radiotherapy planning.
000275766 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000275766 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000275766 650_7 $$2Other$$aFAPI-PET/CT
000275766 650_7 $$2Other$$aOncologic management
000275766 650_7 $$2Other$$aRadiation oncology
000275766 650_7 $$2Other$$aTreatment planning
000275766 773__ $$0PERI:(DE-600)2276891-9$$a10.1016/j.cpet.2023.03.003$$gp. S1556859823000299$$n3$$p369-380$$tPET clinics$$v18$$x1556-8598$$y2023
000275766 909CO $$ooai:inrepo02.dkfz.de:275766$$pVDB
000275766 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000275766 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000275766 9141_ $$y2023
000275766 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPET CLIN : 2022$$d2023-08-23
000275766 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-23
000275766 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-23
000275766 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-23
000275766 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2023-08-23
000275766 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-23
000275766 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-23
000275766 9202_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000275766 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000275766 980__ $$ajournal
000275766 980__ $$aVDB
000275766 980__ $$aI:(DE-He78)E050-20160331
000275766 980__ $$aUNRESTRICTED